A drug identification protocol for type 2 diabetes based on gene expression signatures

Details for Australian Patent Application No. 2010217197 (hide)

Owner Verva Pharmaceuticals Ltd

Inventors Walder, Ken; Konstantopoulos, Nicky; Collier, Greg Royce

Agent Davies Collison Cave

Pub. Number AU-A-2010217197

PCT Pub. Number WO2010/096875

Priority 61/156,149 27.02.09 US

Filing date 25 February 2010

Wipo publication date 2 September 2010

International Classifications

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

Event Publications

28 July 2011 PCT application entered the National Phase

  PCT publication WO2010/096875 Priority application(s): WO2010/096875

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010217198-Locking mechanism, for a padlock for example, in which a shackle can be severed for luggage inspection and then relocked

2010217196-Use of benzodioxole derivatives and Bt toxins in the control of pets